Comments
Peregrine drug doubles lung cancer survival in trial
08.09.2012. | (Reuters) - A small trial of Peregrine Pharmaceuticals Inc's experimental drug, bavituximab, showed that it doubled the length of time lung cancer patients survived, supporting the company's plans to conduct a larger study....
